Go online to PeerView.com/MWJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Dr. Alok Khorana provide a brief recap of recent developments with DOACs in cancer-associated VTE, including evidence presented at the American Society of Clinical Oncology 2020 Annual Meeting. Dr. Khorana comments on these findings and offers thoughts on how to integrate novel oral anticoagulants for personalized management of patients with elevated-risk malignancies such as gastrointestinal and hematologic cancers, among others. Upon completion of this activity, participants will be able to: Review major patient- and treatment-related risk factors for cancer-associated VTE using established diagnostic tools to identify patients for initial treatment or thromboprophylaxis, Evaluate current evidence and guidelines for prevention and treatment of cancer-associated VTE in routine clinical practice, Select a safe and effective anticoagulation regimen including DOACs as initial VTE therapy and/or thromboprophylaxis for managing VTE in patients with gastrointestinal, hematologic, and other malignancies.
View all episodes
